ALC vs ESLOY: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ESLOY is the larger of the two ($87.82B market cap): the incumbent the market prices for continued execution (21.58x forward earnings, beta 0.54). ALC is the smaller challenger ($35.78B), priced similarly on forward earnings (19.08x): more room to run, but more to prove. If the story you believe is ALC's (Demographics that do not switch off), ALC is the more direct way to own it; if it is ESLOY's (AI glasses and the Meta partnership), ESLOY is.

ALC vs ESLOY: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricALCESLOYWhat it tells you
Market cap$35.78B$87.82BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E19.0821.58Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E54.3630.70Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.720.54Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range49% of range16% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.652.00How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how ALC and ESLOY affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALC and ESLOY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALC and ESLOY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Alcon Inc. (ALC) do?

Alcon makes the things an ophthalmologist and an optometrist use every day. The Surgical division sells cataract equipment (the Unity VCS and CS platforms, LenSx femtosecond lasers, the ARGOS biometer, NGENUITY 3D visualization, the Constellation vitreoretinal system) plus the intraocular lenses that get implanted during those procedures, including the PanOptix and Vivity presbyopia-correcting families and the newer Clareon TruPlus monofocal and toric lenses. The Vision Care division sells contact lenses (Precision1, Precision7, Dailies Total1, Total30) and ocular health products (Systane dry eye drops, allergy and lens care lines, and the recently launched Tryptyr dry eye drug). In the third quarter of 2026 the split was roughly $1.5 billion Surgical and $1.2 billion Vision Care on $2.7 billion of total sales, so Surgical is the larger side but not overwhelmingly so. The company is headquartered in Geneva, employs about 25,000 people, traces its roots to a 1945 Fort Worth pharmacy, and has been independent since Novartis spun it off in April 2019. It passed 175 million cumulative IOL implants in March 2026.

Full ALC guide

What does EssilorLuxottica (ESLOY) do?

EssilorLuxottica is the world's largest eyewear company. It was formed in 2018 when French lens maker Essilor merged with Italian frame maker Luxottica, and it now covers almost every step between an eye exam and a pair of glasses. It designs and makes prescription lenses (Varilux, Crizal, Transitions, Stellest for children's myopia), owns frame and sunglass brands such as Ray-Ban, Oakley, Persol and Oliver Peoples, makes licensed frames for Chanel, Prada and others, and runs retail chains including LensCrafters, Sunglass Hut, Target Optical in the US and Salmoiraghi & Viganò in Italy. Through its partnership with Meta it also makes Ray-Ban Meta and Oakley Meta AI glasses, and it sells Nuance Audio hearing glasses. ESLOY is a sponsored ADR on the OTC market: one ADR represents half an ordinary share listed in Paris under EL, and it trades in US dollars while the company reports in euros.

Full ESLOY guide

ALC vs ESLOY: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • ALC drivers: Demographics that do not switch off; An unusually dense 2026 product cycle.
  • ESLOY drivers: AI glasses and the Meta partnership; Myopia management and medtech.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The immediate risk is that soft cataract and premium-lens volumes are not a 2026 phenomenon, in which case growth guidance gets revised down again after multiple cuts in 2025 and 2026; implantables already shrank 2% in the September quarter. For ESLOY, wearables are the largest swing factor.

ALC or ESLOY: which should you pick?

With growth, valuation and volatility this close (or not yet reported for one side), the drivers above are what separate ALC from ESLOY. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALC and ESLOY guides.

ALC vs ESLOY: the full fundamentals

ALC. The two P/E figures tell the whole disagreement. Trailing GAAP earnings are depressed by amortization from the Novartis separation and by the cost of running several product launches at once, which is why the stock screens at roughly 54.5 times trailing and roughly 19 times forward. Gross margin sits near 58% and cash generation is steady, so the open question is the business's growth rate after the 2026 launch wave, with management already listing 2027 headwinds. Shares have recovered from near the bottom of a ~$61.83 to ~$87.64 52-week range toward the middle, against an average analyst target around $81 from 16 analysts.

ESLOY. Trailing reported earnings understate the business because they include amortisation from the 2018 merger and other acquisitions; adjusted net profit was ~€3.16 billion in 2025 and ~€1.92 billion in the first half of 2026. On forward estimates the ADR trades near ~22x, down from well above 40x at the late 2025 peak and roughly in line with large European consumer health names. EV/EBITDA is ~18x on Yahoo's figures, and the price is ~3x sales. The two analysts Yahoo tracks on the ADR have a mean target of ~$132.50, well above the ~$96 close. Net debt of ~€13.4 billion is about 2x EBITDA. Each ESLOY ADR equals 0.5 ordinary shares, so the ADR price is roughly half the Paris price converted into dollars at ~$1.11 per euro.

Headline figures (approximate, November 2026): ALC shows revenue (ttm) ~$11.0 billion, up ~5% year over year in Q3 2026, q3 2026 sales ~$2.74 billion (Surgical ~$1.5 billion, Vision Care ~$1.2 billion); core diluted EPS $0.91 vs $0.89 expected, margins ~58% gross, ~13% operating, ~6% net (TTM GAAP); Q3 core operating margin 21.8%, earnings per share ~$1.37 trailing GAAP; ~$3.49 core expected for 2026 and ~$3.90 for 2027; ESLOY shows revenue (ttm) ~€29.3B (+5.7% latest quarter, reported), q3 2026 revenue ~€7.49B (+7.2% constant currency), margins (ttm: gross / operating / net) ~60% / ~13% / ~8.5%, net income (ttm) ~€2.5B.

The bottom line: ALC vs ESLOY

ALC and ESLOY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ALC and ESLOY exposure against your real portfolio. It is not an investment adviser.

Wondering how ALC or ESLOY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Alcon Inc.

Ask Walnut's AI anything about ALC and see how it fits what you own.

FAQ

What is the difference between ALC and ESLOY?

+

Alcon makes the things an ophthalmologist and an optometrist use every day. EssilorLuxottica is the world's largest eyewear company. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ALC or ESLOY the better stock?

+

Neither is universally better. ESLOY is the larger incumbent; ALC is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ALC or ESLOY?

+

On forward P/E (as of November 2026), ALC trades at 19.08x and ESLOY at 21.58x, so ALC is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ALC and ESLOY?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ALC vs ESLOY?

+

ALC: The immediate risk is that soft cataract and premium-lens volumes are not a 2026 phenomenon, in which case growth guidance gets revised down again after multiple cuts in 2025 and 2026; implantables already shrank 2% in the September quarter. The gap between reported and core earnings is wide (trailing GAAP EPS around $1.37 against 2026 core estimates near $3.49), so bulls and bears citing Alcon's P/E are often quoting about 55 times and about 19 times for the same stock as of November 2026. Balance-sheet debt is ~$5.3 billion against ~$1.8 billion of cash. Management has named 2027 headwinds: lapping the Unity rollout, the non-recurring ~$60 million of 2026 tariff refunds, a $15 million milestone payment, memory and resin inflation, and dilution from Neurotech. As a Swiss-domiciled company reporting in dollars, currency moves swing reported growth several points in either direction. Competition is intense on both sides of the business: Johnson & Johnson MedTech and Bausch + Lomb in surgical and IOLs, Cooper Companies and J&J in contact lenses, with international contact lens markets growing only 1% to 2%. Two attempted deals failed in quick succession (LENSAR terminated in March 2026 over FTC opposition, and STAAR Surgical shareholders rejected Alcon's $30.75 per share offer in January 2026), and the ENCELTO ramp is the next test of whether the company can add inorganic growth. ESLOY: Wearables are the largest swing factor. Growth slowed from nearly 100% in the second quarter to 20% in the third, and analysts expect a tough fourth-quarter comparison. Google has announced Gemini-powered glasses with partners including Warby Parker and Gentle Monster, and Bloomberg has reported Apple is working toward its own glasses for 2027. If smart glasses hardware becomes a commodity, EssilorLuxottica's role as Meta's manufacturer could earn less. The company also depends on Meta for the AI and software, and Meta paused Ray-Ban Display launches outside the US over supply shortages, which led Baader to downgrade the stock. US tariffs weigh on frames made in Italy and China. The dollar matters twice: North America is ~43% of revenue, so a weak dollar trims reported euro sales, and the ADR price also moves with the euro/dollar rate. The valuation (~31x trailing earnings) leaves little room for a miss. Control of Delfin, the family holding company that is the largest shareholder, is being contested among Del Vecchio heirs, and a change in who runs it could change how the group is governed. Net debt has climbed to ~€13.4 billion on acquisitions, and the scrip dividend slowly dilutes holders. French withholding tax applies to dividends paid to US ADR holders, and OTC trading in ESLOY is thinner than in the Paris shares.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ALC or ESLOY; figures are approximate and dated (as of November 2026). Verify current data before investing.